| # | Title | Journal | Year | Citations |
|---|
| 1 | A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2004 | 2,112 |
| 2 | The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes | Clinical Cancer Research | 2007 | 1,786 |
| 3 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
| 4 | Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology | Proceedings of the National Academy of Sciences of the United States of America | 2014 | 736 |
| 5 | Microparticles in Hemostasis and Thrombosis | Circulation Research | 2011 | 717 |
| 6 | Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression | Journal of Clinical Oncology | 2007 | 607 |
| 7 | Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer | Clinical Breast Cancer | 2009 | 546 |
| 8 | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial | Blood | 2020 | 436 |
| 9 | Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis | Blood | 2016 | 403 |
| 10 | The role of the ubiquitin-proteasome pathway in apoptosis | Cell Death and Differentiation | 1999 | 365 |
| 11 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma | Blood | 2016 | 347 |
| 12 | New insights into the mechanisms of venous thrombosis | Journal of Clinical Investigation | 2012 | 322 |
| 13 | The proteasome as a target for cancer therapy | Clinical Cancer Research | 2003 | 299 |
| 14 | Molecular portraits and the family tree of cancer | Nature Genetics | 2002 | 275 |
| 15 | Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741 | Journal of Clinical Oncology | 2008 | 274 |
| 16 | The Role of Tissue Factor and Factor VIIa in Hemostasis | Anesthesia and Analgesia | 2009 | 272 |
| 17 | Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 261 |
| 18 | Current Landscape of Immunotherapy in Breast Cancer | JAMA Oncology | 2019 | 260 |
| 19 | THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY | Annual Review of Pharmacology and Toxicology | 2006 | 251 |
| 20 | Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy | Blood | 2008 | 250 |
| 21 | Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors | Blood | 2016 | 246 |
| 22 | Factors associated with survival in a contemporary adult sickle cell disease cohort | American Journal of Hematology | 2014 | 235 |
| 23 | EGFR associated expression profiles vary with breast tumor subtype | BMC Genomics | 2007 | 234 |
| 24 | Deregulation of DUX4 and ERG in acute lymphoblastic leukemia | Nature Genetics | 2016 | 231 |
| 25 | Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients | Journal of Thrombosis and Haemostasis | 2012 | 228 |
| 26 | The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer | Oncologist | 2007 | 218 |
| 27 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States | Blood | 2017 | 210 |
| 28 | Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research | Oncologist | 2013 | 197 |
| 29 | Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia | Blood | 2008 | 193 |
| 30 | American Joint Committee on Cancer Tumor–Node–Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome | Journal of the National Cancer Institute | 2005 | 185 |
| 31 | Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism | Thrombosis Research | 2010 | 184 |
| 32 | Understanding and treating triple-negative breast cancer | Oncology | 2008 | 179 |
| 33 | Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer | Blood | 2012 | 176 |
| 34 | Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem | Hematology American Society of Hematology Education Program | 2007 | 166 |
| 35 | Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension | Haematologica | 2008 | 162 |
| 36 | Myosteatosis and prognosis in cancer: Systematic review and meta-analysis | Critical Reviews in Oncology/Hematology | 2020 | 160 |
| 37 | Tissue factor and thrombosis: The clot starts here | Thrombosis and Haemostasis | 2010 | 150 |
| 38 | Renal cell carcinoma | Current Opinion in Oncology | 1998 | 144 |
| 39 | Muscle‐invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base | BJU International | 2014 | 132 |
| 40 | Interplay between coagulation and vascular inflammation in sickle cell disease | British Journal of Haematology | 2013 | 127 |
| 41 | Racial Differences in Mortality Among Medicare Recipients After Treatment for Localized Prostate Cancer | Journal of the National Cancer Institute | 2003 | 125 |
| 42 | The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer | Breast Cancer Research | 2002 | 123 |
| 43 | Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL | Cancer Research | 2013 | 118 |
| 44 | Trimethylamine N‐oxide: breathe new life | British Journal of Pharmacology | 2018 | 116 |
| 45 | Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity | Thrombosis Research | 2012 | 115 |
| 46 | Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma | Clinical Cancer Research | 2007 | 112 |
| 47 | Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice | Journal of Thrombosis and Haemostasis | 2009 | 111 |
| 48 | Burnout, Moral Distress, Work–Life Balance, and Career Satisfaction among Hematopoietic Cell Transplantation Professionals | Biology of Blood and Marrow Transplantation | 2018 | 108 |
| 49 | Treatment of Older Patients With Head and Neck Cancer: A Review | Oncologist | 2013 | 107 |
| 50 | Microparticle analysis in disorders of hemostasis and thrombosis | Cytometry Part A: the Journal of the International Society for Analytical Cytology | 2016 | 104 |
